Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company lifted its stake in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 41.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 24,349 shares of the company’s stock after purchasing an additional 7,096 shares during the period. The Manufacturers Life Insurance Company’s holdings in Ventyx Biosciences were worth $56,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Norden Group LLC acquired a new stake in shares of Ventyx Biosciences in the 1st quarter worth $59,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Ventyx Biosciences in the first quarter valued at about $72,000. SG Americas Securities LLC acquired a new stake in Ventyx Biosciences during the second quarter worth about $32,000. Rhumbline Advisers raised its stake in Ventyx Biosciences by 38.0% during the second quarter. Rhumbline Advisers now owns 90,331 shares of the company’s stock worth $209,000 after purchasing an additional 24,885 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Ventyx Biosciences during the second quarter worth about $58,000. 97.88% of the stock is currently owned by institutional investors and hedge funds.

Ventyx Biosciences Stock Down 5.9 %

Shares of NASDAQ VTYX opened at $2.39 on Tuesday. The business’s 50 day moving average is $2.20 and its two-hundred day moving average is $3.05. Ventyx Biosciences, Inc. has a 52-week low of $1.79 and a 52-week high of $17.00. The firm has a market cap of $168.90 million, a price-to-earnings ratio of -0.86 and a beta of 0.36.

Ventyx Biosciences (NASDAQ:VTYX) last announced its earnings results on Thursday, August 8th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.12. Analysts anticipate that Ventyx Biosciences, Inc. will post -2.14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on VTYX shares. Wells Fargo & Company cut their price target on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Canaccord Genuity Group cut their target price on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Finally, HC Wainwright restated a “neutral” rating and issued a $6.00 target price on shares of Ventyx Biosciences in a research report on Tuesday, October 15th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $8.29.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.